Patent US4705846A successfully refreshed from Google Patents.
US4705846A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel renin inhibiting peptides having a gamma lactam pseudo dipeptide insert
Assignee: Pharmacia and Upjohn Co
•
Filing: 1986-03-27
•
Granted: 1987-11-10
•
Expires: 2006-03-27
Abstract
Abstract The present invention provides novel renin-inhibiting peptides of the formula X-A 6 -B 7 -C 8 -D 9 -E 10 -F 11 -G 12 -H 13 -I 14 -Z, having a lactam pseudo-dipeptide at C 8 -D 9 positions, X and Z are terminal groups, and the remaining variables are absent or are amino acid residues. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension.
Inventors
- 👤 Suvit Thaisrivongs
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 15:23
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; A; A61; A61P; A61P5/00; A61P5/38; A61P9/00; A61P9/12; C07K; C07K5/00; C07K5/02; C07K5/0227; C07K5/04; C07K5/06; C07K5/06139; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/86
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
1795 words
A renin inhibitory peptide of the formula X--A 6 --B 7 --C 8 --D 9 --E 10 --F 11 --G 12 --H 13 --I 14 --Z, wherein X is (a) hydrogen, (b) C 1 -C 5 alkyl (c) R 5 --O--CH 2 --C(O)--, (d) R 5 --CH 2 --O--C(O)--, (e) R 5 --O--C(O)--, (f) R 5 --(CH 2 ) n --C(O)--, (g) R 4 N(R 4 )--(CH 2 ) n --C(O)--, (h) R 5 --SO 2 --(CH 2 ) q --C(O)--, (i) R 5 --SO 2 --(CH 2 ) q --O--C(O)--, or (j) R 6 --(CH 2 ) i --C(O)--; wherein A 6 is absent or a divalent moiety of the formula XL 1 , XL 2 , or XL 2a ##STR5## wherein B 7 is absent or a divalent moiety of the formula XL b ##STR6## wherein C 8 --D 9 is XL 3 or XL 3a , or ##STR7## wherein C 8 --D 9 is a monovalent moiety of the formula XL 3b when X, A 6 , and B 7 are absent; ##STR8## wherein E 10 --F 11 is a divalent moiety of the formula XL 6 , XL 6a , XL 6b , XL 6c , XL 6d or XL 6e ; ##STR9## wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G 12 is absent or a divalent moiety of the formula XL 4 or XL 4a ; ##STR10## wherein H 13 is absent or a divalent moiety of the formula XL 4 ; ##STR11## wherein I 14 is absent or a divalent moiety of the formula XL 5 ; ##STR12## wherein Z is (a) --O--R 10 , (b) --N(R 4 )R 14 , or (c) C 4 -C 8 cyclic amino; wherein R is (a) isopropyl, (b) isobutyl, (c) phenylmethyl, or (d) C 3 -C 7 cycloalkyl; wherein R 1 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) aryl, (d) C 3 -C 7 cycloalkyl, (e) --Het, (f) C 1 -C 3 alkoxy, or (g) C 1 -C 3 alkylthio; wherein R 2 is (a) hydrogen, or (b) --CH(R 3 )R 4 ; wherein R 3 is (a) hydrogen, (b) hydroxy, (c) C 1 -C 5 alkyl, (d) C 3 -C 7 cycloalkyl, (e) aryl, (f) --Het, (g) C 1 -C 3 alkoxy, or (h) C 1 -C 3 alkylthio; wherein R 4 at each occurrence is the same or different and is (a) hydrogen, or (b) C 1 -C 5 alkyl; wherein R 5 is (a) C 1 -C 6 alkyl, (b) C 3 -C 7 cycloalkyl, (c) aryl, (d) --Het, or (e) 5-oxo-2-pyrrolidinyl; wherein R 6 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) --(CH 2 ) p --aryl, (d) --(CH 2 ) p --Het, (e) --(CH 2 ) p --C 3 -C 7 cycloalkyl, (f) 1- or 2-adamantyl, (g) --S--aryl, (h) --S--C 3 -C 7 cycloalkyl, or (i) --S--C 1 -C 6 --alkyl; wherein R 7 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) hydroxy, (d) amino C 1 -C 4 alkyl--, (e) guanidinyl C 1 -C 3 alkyl--, (f) aryl, (g) --Het, (h) methylthio, (i) --(CH 2 ) p --C 3 -C 7 cycloalkyl, or (j) amino; wherein R 8 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) hydroxy, (d) aryl, (e) --Het, (f) guanidinyl C 1 -C 3 alkyl--, or (g) --(CH 2 ) p --C 3 -C 7 cycloalkyl; wherein R 9 is (a) hydrogen, (b) hydroxy, (c) amino C 1 -C 4 alkyl--, or (d) guanidinyl C 1 -C 3 alkyl--; wherein R 10 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) --(CH 2 ) n R 16 , (d) --(CH 2 ) n R 17 , (e) C 3 -C 7 cycloalkyl, (f) a pharmaceutically acceptable cation, (g) --CH(R 25 )--CH 2 --R 15 , or (h) --CH 2 --CH(R 12 )--R 15 ; wherein R 11 is --R or --R 2 ; wherein R 12 is --(CH 2 ) n --R 13 ; wherein R 13 is (a) aryl, (b) amino, (c) mono-, di or tri-C 1 -C 3 alkylamino, (d) --Het, (e) C 1 -C 5 alkyl (f) C 3 -C 7 cycloalkyl, (g) C 2 -C 5 alkenyl, (h) C 3 -C 7 cycloalkenyl, (i) hydroxy, (j) C 1 -C 3 alkoxy, (k) C 1 -C 3 alkanoyloxy, (l) mercapto, (m) C 1 -C 3 alkylthio, (n) --COOH, (o) --CO--O--C 1 -C 6 alkyl, (p) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (q) --CO--NR 22 R 26 ; (r) C 4 -C 7 cyclic amino, (s) C 4 -C 7 cycloalkylamino, (t) guanidyl, (u) cyano, (v) N-cyanoguanidyl, (w) cyanoamino, (x) (hydroxy C 2 -C 4 alkyl)amino, or (y) di-(hydroxyC 2 -C 4 alkyl)amino; wherein R 14 is (a) hydrogen, (b) C 1 -C 10 alkyl, (c) --(CH 2 ) n --R 18 , (d) --(CH 2 ) n --R 19 , (e) --CH(R 25 )--CH 2 --R 15 , (f) --CH 2 --CH(R 12 )--R 15 , (g) (hydroxy C 1 -C 8 alkyl), or (h) (C 1 -C 3 alkoxy)C 1 -C 8 alkyl; wherein R 15 is (a) hydroxy, (b) C 3 -C 7 cycloalkyl, (c) aryl, (d) amino, (e) mono-, di-, or tri-C 1 -C 3 alkylamino, (f) mono- or di-[hydroxy C 2 -C 4 alkyl]amino, (g) --Het, (h) C 1 -C 3 alkoxy--, (i) C 1 -C 3 alkanoyloxy--, (j) mercapto, (k) C 1 -C 3 alkylthio--, (l) C 1 -C 5 alkyl, (m) C 4 -C 7 cyclic amino, (n) C 4 -C 7 cycloalkylamino, (o) C 1 -C 5 alkenyloxy, (p) C 3 -C 7 cycloalkenyl; wherein R 16 is (a) aryl, (b) amino, (c) mono- or di-C 1 -C 3 alkylamino, (d) hydroxy, (e) C 3 -C 7 cycloalkyl, (f) C 4 -C 7 cyclic amino, or (g) C 1 -C 3 alkanoyloxy; wherein R 17 is (a) --Het, (b) C 2 -C 5 alkenyl, (c) C 3 -C 7 cycloalkenyl, (d) C 1 -C 3 alkoxy, (e) mercapto, (f) C 1 -C 3 alkylthio, (g) --COOH, (h) --CO--O--C 1 -C 6 alkyl, (i) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (j) --CO--NR 22 R 26 , (k) tri-C 1 -C 3 alkylamino, (l) guanidyl, (m) cyano, (n) N-cyanoguanidyl, (o) (hydroxy C 2 -C 4 alkyl)amino, (p) di-(hydroxy C 2 -C 4 alkyl)amino, or (q) cyanoamino; wherein R 18 is (a) amino, (b) mono-, or di-C 1 -C 3 alkylamino, (c) C 4 -C 7 cyclic amino; or (d) C 4 -C 7 cycloalkylamino; wherein R 19 is (a) aryl, (b) --Het, (c) tri-C 1 -C 3 alkylamino, (d) C 3 -C 7 cycloalkyl, (e) C 2 -C 5 alkenyl, (f) C 3 -C 7 cycloalkenyl, (g) hydroxy, (h) C 1 -C 3 alkoxy, (i) C 1 -C 3 alkanoyloxy, (j) mercapto, (k) C 1 -C 3 alkylthio, (l) --COOH, (m) --CO--O--C 1 -C 6 alkyl, (n) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (o) --CO--NR 22 R 26 , (p) guanidyl, (q) cyano, (r) N-cyanoguanidyl, (s) cyanoamino, (t) (hydroxy C 2 -C 4 alkyl)amino, (u) di-(hydroxy C 2 -C 4 alkyl)amino; or (v) --SO 3 H; wherein R 20 is (a) hydrogen, (b) C 1 -C 5 alkyl, or (c) aryl--C 1 -C 5 alkyl; wherein R 21 is (a) --NH 2 , or (b) --OH; wherein R 22 is (a) hydrogen, or (b) C 1 -C 3 alkyl; wherein R 23 is (a) --(CH 2 ) n --OH, (b) --(CH 2 ) n --NH 2 , (c) aryl, or (d) C 1 -C 3 alkyl; wherein R 24 is (a) --R 1 , (b) --(CH 2 ) n --OH, or (c) --(CH 2 ) n --NH 2 ; wherein R 25 is (a) hydrogen, (b) C 1 -C 3 alkyl, or (c) phenyl--C 1 -C 3 alkyl; wherein R 26 is (a) hydrogen, (b) C 1 -C 3 alkyl, or (c) phenyl--C 1 -C 3 alkyl; wherein m is one or two; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to 2 inclusive; wherein q is 1 to 5, inclusive; wherein Q is (a) --CH 2 --, (b) --CH(OH)--, (c) --O--, or (d) --S--; and wherein M is (a) --CO--, or (b) --CH 2 --; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following: (a) C 1 -C 3 alkyl, (b) hydroxy, (c) C 1 -C 3 alkoxy, (d) halo, (e) amino, (f) mono- or di-C 1 -C 3 alkylamino, (g) --CHO, (h) --COOH, (i) COOR 26 , (j) CONHR 26 , (k) nitro, (l) mercapto, (m) C 1 -C 3 alkylthio, (n) C 1 -C 3 alkylsulfinyl, (o) C 1 -C 3 alkylsulfonyl, (p) --N(R 4 )--C 1 -C 3 alkylsulfonyl, (q) SO 3 H, (r) SO 2 NH 2 , (s) --CN, or (t) --CH 2 NH 2 ; wherein --Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following: (i) C 1 -C 6 alkyl, (ii) hydroxy, (iii) trifluoromethyl, (iv) C 1 -C 4 alkoxy, (v) halo, (vi) aryl, (vii) aryl C 1 -C 4 alkyl--, (viii) amino, (ix) mono- or di-C 1 -C 4 alkylamino, and (x) C 1 -C 5 alkanoyl; with the overall provisos that (1) R 18 or R 19 is hydroxy, mercapto, or amino, or a mono-substituted nitrogen containing group bonded through the nitrogen only when n is not one; (2) R 12 is --(CH 2 ) n --R 13 and n is zero and both R 13 and R 15 are oxygen-, nitrogen-, or sulfur-containing substituents bonded through the hetero atom, only when the hetero atom is not also bonded to hydrogen; (3) R 17 or R 19 is --COOH only when n for that moiety is other than zero; (4) R 16 or R 17 is an amino-containing substituent, hydroxy, mercapto, or --Het bonded through the hetero atom only when n for that substituent is an integer from two to five, inclusive; (5) when R 12 is --(CH 2 ) n --R 13 and n is zero, then R 13 and R 15 cannot both be --COOH; and (6) R 17 or R 19 is --Het, only when --Het is other than cyclic amino; or a carboxy-, amino-, or other reactive group-protected form thereof; or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
1795 words
A renin inhibitory peptide of the formula X--A 6 --B 7 --C 8 --D 9 --E 10 --F 11 --G 12 --H 13 --I 14 --Z, wherein X is (a) hydrogen, (b) C 1 -C 5 alkyl (c) R 5 --O--CH 2 --C(O)--, (d) R 5 --CH 2 --O--C(O)--, (e) R 5 --O--C(O)--, (f) R 5 --(CH 2 ) n --C(O)--, (g) R 4 N(R 4 )--(CH 2 ) n --C(O)--, (h) R 5 --SO 2 --(CH 2 ) q --C(O)--, (i) R 5 --SO 2 --(CH 2 ) q --O--C(O)--, or (j) R 6 --(CH 2 ) i --C(O)--; wherein A 6 is absent or a divalent moiety of the formula XL 1 , XL 2 , or XL 2a ##STR5## wherein B 7 is absent or a divalent moiety of the formula XL b ##STR6## wherein C 8 --D 9 is XL 3 or XL 3a , or ##STR7## wherein C 8 --D 9 is a monovalent moiety of the formula XL 3b when X, A 6 , and B 7 are absent; ##STR8## wherein E 10 --F 11 is a divalent moiety of the formula XL 6 , XL 6a , XL 6b , XL 6c , XL 6d or XL 6e ; ##STR9## wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G 12 is absent or a divalent moiety of the formula XL 4 or XL 4a ; ##STR10## wherein H 13 is absent or a divalent moiety of the formula XL 4 ; ##STR11## wherein I 14 is absent or a divalent moiety of the formula XL 5 ; ##STR12## wherein Z is (a) --O--R 10 , (b) --N(R 4 )R 14 , or (c) C 4 -C 8 cyclic amino; wherein R is (a) isopropyl, (b) isobutyl, (c) phenylmethyl, or (d) C 3 -C 7 cycloalkyl; wherein R 1 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) aryl, (d) C 3 -C 7 cycloalkyl, (e) --Het, (f) C 1 -C 3 alkoxy, or (g) C 1 -C 3 alkylthio; wherein R 2 is (a) hydrogen, or (b) --CH(R 3 )R 4 ; wherein R 3 is (a) hydrogen, (b) hydroxy, (c) C 1 -C 5 alkyl, (d) C 3 -C 7 cycloalkyl, (e) aryl, (f) --Het, (g) C 1 -C 3 alkoxy, or (h) C 1 -C 3 alkylthio; wherein R 4 at each occurrence is the same or different and is (a) hydrogen, or (b) C 1 -C 5 alkyl; wherein R 5 is (a) C 1 -C 6 alkyl, (b) C 3 -C 7 cycloalkyl, (c) aryl, (d) --Het, or (e) 5-oxo-2-pyrrolidinyl; wherein R 6 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) --(CH 2 ) p --aryl, (d) --(CH 2 ) p --Het, (e) --(CH 2 ) p --C 3 -C 7 cycloalkyl, (f) 1- or 2-adamantyl, (g) --S--aryl, (h) --S--C 3 -C 7 cycloalkyl, or (i) --S--C 1 -C 6 --alkyl; wherein R 7 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) hydroxy, (d) amino C 1 -C 4 alkyl--, (e) guanidinyl C 1 -C 3 alkyl--, (f) aryl, (g) --Het, (h) methylthio, (i) --(CH 2 ) p --C 3 -C 7 cycloalkyl, or (j) amino; wherein R 8 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) hydroxy, (d) aryl, (e) --Het, (f) guanidinyl C 1 -C 3 alkyl--, or (g) --(CH 2 ) p --C 3 -C 7 cycloalkyl; wherein R 9 is (a) hydrogen, (b) hydroxy, (c) amino C 1 -C 4 alkyl--, or (d) guanidinyl C 1 -C 3 alkyl--; wherein R 10 is (a) hydrogen, (b) C 1 -C 5 alkyl, (c) --(CH 2 ) n R 16 , (d) --(CH 2 ) n R 17 , (e) C 3 -C 7 cycloalkyl, (f) a pharmaceutically acceptable cation, (g) --CH(R 25 )--CH 2 --R 15 , or (h) --CH 2 --CH(R 12 )--R 15 ; wherein R 11 is --R or --R 2 ; wherein R 12 is --(CH 2 ) n --R 13 ; wherein R 13 is (a) aryl, (b) amino, (c) mono-, di or tri-C 1 -C 3 alkylamino, (d) --Het, (e) C 1 -C 5 alkyl (f) C 3 -C 7 cycloalkyl, (g) C 2 -C 5 alkenyl, (h) C 3 -C 7 cycloalkenyl, (i) hydroxy, (j) C 1 -C 3 alkoxy, (k) C 1 -C 3 alkanoyloxy, (l) mercapto, (m) C 1 -C 3 alkylthio, (n) --COOH, (o) --CO--O--C 1 -C 6 alkyl, (p) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (q) --CO--NR 22 R 26 ; (r) C 4 -C 7 cyclic amino, (s) C 4 -C 7 cycloalkylamino, (t) guanidyl, (u) cyano, (v) N-cyanoguanidyl, (w) cyanoamino, (x) (hydroxy C 2 -C 4 alkyl)amino, or (y) di-(hydroxyC 2 -C 4 alkyl)amino; wherein R 14 is (a) hydrogen, (b) C 1 -C 10 alkyl, (c) --(CH 2 ) n --R 18 , (d) --(CH 2 ) n --R 19 , (e) --CH(R 25 )--CH 2 --R 15 , (f) --CH 2 --CH(R 12 )--R 15 , (g) (hydroxy C 1 -C 8 alkyl), or (h) (C 1 -C 3 alkoxy)C 1 -C 8 alkyl; wherein R 15 is (a) hydroxy, (b) C 3 -C 7 cycloalkyl, (c) aryl, (d) amino, (e) mono-, di-, or tri-C 1 -C 3 alkylamino, (f) mono- or di-[hydroxy C 2 -C 4 alkyl]amino, (g) --Het, (h) C 1 -C 3 alkoxy--, (i) C 1 -C 3 alkanoyloxy--, (j) mercapto, (k) C 1 -C 3 alkylthio--, (l) C 1 -C 5 alkyl, (m) C 4 -C 7 cyclic amino, (n) C 4 -C 7 cycloalkylamino, (o) C 1 -C 5 alkenyloxy, (p) C 3 -C 7 cycloalkenyl; wherein R 16 is (a) aryl, (b) amino, (c) mono- or di-C 1 -C 3 alkylamino, (d) hydroxy, (e) C 3 -C 7 cycloalkyl, (f) C 4 -C 7 cyclic amino, or (g) C 1 -C 3 alkanoyloxy; wherein R 17 is (a) --Het, (b) C 2 -C 5 alkenyl, (c) C 3 -C 7 cycloalkenyl, (d) C 1 -C 3 alkoxy, (e) mercapto, (f) C 1 -C 3 alkylthio, (g) --COOH, (h) --CO--O--C 1 -C 6 alkyl, (i) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (j) --CO--NR 22 R 26 , (k) tri-C 1 -C 3 alkylamino, (l) guanidyl, (m) cyano, (n) N-cyanoguanidyl, (o) (hydroxy C 2 -C 4 alkyl)amino, (p) di-(hydroxy C 2 -C 4 alkyl)amino, or (q) cyanoamino; wherein R 18 is (a) amino, (b) mono-, or di-C 1 -C 3 alkylamino, (c) C 4 -C 7 cyclic amino; or (d) C 4 -C 7 cycloalkylamino; wherein R 19 is (a) aryl, (b) --Het, (c) tri-C 1 -C 3 alkylamino, (d) C 3 -C 7 cycloalkyl, (e) C 2 -C 5 alkenyl, (f) C 3 -C 7 cycloalkenyl, (g) hydroxy, (h) C 1 -C 3 alkoxy, (i) C 1 -C 3 alkanoyloxy, (j) mercapto, (k) C 1 -C 3 alkylthio, (l) --COOH, (m) --CO--O--C 1 -C 6 alkyl, (n) --CO--O--CH 2 --(C 1 -C 3 alkyl)--N(C 1 -C 3 alkyl) 2 , (o) --CO--NR 22 R 26 , (p) guanidyl, (q) cyano, (r) N-cyanoguanidyl, (s) cyanoamino, (t) (hydroxy C 2 -C 4 alkyl)amino, (u) di-(hydroxy C 2 -C 4 alkyl)amino; or (v) --SO 3 H; wherein R 20 is (a) hydrogen, (b) C 1 -C 5 alkyl, or (c) aryl--C 1 -C 5 alkyl; wherein R 21 is (a) --NH 2 , or (b) --OH; wherein R 22 is (a) hydrogen, or (b) C 1 -C 3 alkyl; wherein R 23 is (a) --(CH 2 ) n --OH, (b) --(CH 2 ) n --NH 2 , (c) aryl, or (d) C 1 -C 3 alkyl; wherein R 24 is (a) --R 1 , (b) --(CH 2 ) n --OH, or (c) --(CH 2 ) n --NH 2 ; wherein R 25 is (a) hydrogen, (b) C 1 -C 3 alkyl, or (c) phenyl--C 1 -C 3 alkyl; wherein R 26 is (a) hydrogen, (b) C 1 -C 3 alkyl, or (c) phenyl--C 1 -C 3 alkyl; wherein m is one or two; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to 2 inclusive; wherein q is 1 to 5, inclusive; wherein Q is (a) --CH 2 --, (b) --CH(OH)--, (c) --O--, or (d) --S--; and wherein M is (a) --CO--, or (b) --CH 2 --; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following: (a) C 1 -C 3 alkyl, (b) hydroxy, (c) C 1 -C 3 alkoxy, (d) halo, (e) amino, (f) mono- or di-C 1 -C 3 alkylamino, (g) --CHO, (h) --COOH, (i) COOR 26 , (j) CONHR 26 , (k) nitro, (l) mercapto, (m) C 1 -C 3 alkylthio, (n) C 1 -C 3 alkylsulfinyl, (o) C 1 -C 3 alkylsulfonyl, (p) --N(R 4 )--C 1 -C 3 alkylsulfonyl, (q) SO 3 H, (r) SO 2 NH 2 , (s) --CN, or (t) --CH 2 NH 2 ; wherein --Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following: (i) C 1 -C 6 alkyl, (ii) hydroxy, (iii) trifluoromethyl, (iv) C 1 -C 4 alkoxy, (v) halo, (vi) aryl, (vii) aryl C 1 -C 4 alkyl--, (viii) amino, (ix) mono- or di-C 1 -C 4 alkylamino, and (x) C 1 -C 5 alkanoyl; with the overall provisos that (1) R 18 or R 19 is hydroxy, mercapto, or amino, or a mono-substituted nitrogen containing group bonded through the nitrogen only when n is not one; (2) R 12 is --(CH 2 ) n --R 13 and n is zero and both R 13 and R 15 are oxygen-, nitrogen-, or sulfur-containing substituents bonded through the hetero atom, only when the hetero atom is not also bonded to hydrogen; (3) R 17 or R 19 is --COOH only when n for that moiety is other than zero; (4) R 16 or R 17 is an amino-containing substituent, hydroxy, mercapto, or --Het bonded through the hetero atom only when n for that substituent is an integer from two to five, inclusive; (5) when R 12 is --(CH 2 ) n --R 13 and n is zero, then R 13 and R 15 cannot both be --COOH; and (6) R 17 or R 19 is --Het, only when --Het is other than cyclic amino; or a carboxy-, amino-, or other reactive group-protected form thereof; or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
6 words
3R-Benzyl-2-oxo-1-pyrrolidine-2S-hexanoyl-5S-amino-4S-hydroxy-2S-isopropyl-7-methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
Claim 4
Dependent Claim
6 words
3S-Benzyl-2-oxo-1-pyrrolidine-2S-hexanoyl-5S-amino-4S-hydroxy-2S-isopropyl-7-methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
Claim 5
Dependent Claim
8 words
(R and S)-3-benzyl-3-benzyloxycarbonylamino-2-oxo-1-pyrrolidine-2S-hexanoyl-5S-amino-4S-hydroxy-2S-isopropyl-7-methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
Claim 6
Dependent Claim
8 words
(R and S)-3-benzyl-3-acetylamino-2-oxo-1-pyrrolidine-2S-hexanoyl-5S-amino-4S-hydroxy-2S-isopropyl-7-methyl-octanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
Claim 7
Dependent Claim
6 words
3R-Benzyl-2-oxo-1-pyrrolidine-2S-hexanoyl-4S-amino-3S-hydroxy-6-methyl-heptanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
Claim 8
Dependent Claim
6 words
3S-Benzyl-2-oxo-1-pyrrolidine-2S-hexanoyl-4S-amino-3S-hydroxy-6-methyl-heptanoyl-L-isoleucyl-2-pyridylmethylamide, a compound of claim 1.
References Cited (Backward Citations)
EP0045161A1
Cited
EP0045665A1
Cited
US4424207A
Cited
EP0053017A1
Cited
US4478826A
Cited
EP0077028A2
Cited
EP0077029A2
Cited
US4470971A
Cited
EP0081783B1
Cited
US4479941A
Cited
EP0104041A1
Cited
EP0111266A2
Cited
EP0114993A2
Cited
EP0118223A1
Cited
US4478827A
Cited
US4485099A
Cited
US4477441A
Cited
US4477440A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-11-09 | 1991-05-11 | 1991-11-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-11-09 | 1995-05-11 | 1995-11-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-11-09 | 1999-05-11 | 1999-11-10 | $7700.00 | Window Closed / Lapsed |